Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Acta Neuropathologica
Published in: Acta Neuropathologica 4/2008

Open Access 01-04-2008 | Original Paper

Neuronal pentraxin II is highly upregulated in Parkinson’s disease and a novel component of Lewy bodies

Authors: Linda B. Moran, Lorraine Hickey, Gregory J. Michael, Maria Derkacs, Lynne M. Christian, Michail E. Kalaitzakis, Ronald K. B. Pearce, Manuel B. Graeber

Published in: Acta Neuropathologica | Issue 4/2008

Login to get access

Abstract

Neuronal pentraxin II (NPTX2) is the most highly upregulated gene in the Parkinsonian substantia nigra based on our whole genome expression profiling results. We show here that it is a novel component of Lewy bodies and Lewy neurites in sporadic Parkinson’s disease (PD). NPTX2 is also known as the neuronal activity-regulated protein (Narp), which is secreted and involved in long-term neuronal plasticity. Narp further regulates AMPA receptors which have been found to mediate highly selective non-apoptotic cell death of dopaminergic neurons. NPTX2/Narp is found in close association with alpha-synuclein aggregates in both substantia nigra and cerebral cortex in PD but unlike alpha-synuclein gene expression, which is down-regulated in the Parkinsonian nigra, NPTX2 could represent a driver of the disease process. In view of its profound (>800%) upregulation and its established role in synaptic plasticity as well as dopaminergic nerve cell death, NPTX2 is a very interesting novel player which is likely to be involved in the pathway dysregulation which underlies PD.
Appendix
Available only for authorised users
Literature
1.
Bjartmar L, Huberman AD, Ullian EM, Renteria RC, Liu X, Xu W, Prezioso J, Susman MW, Stellwagen D, Stokes CC, Cho R, Worley P, Malenka RC, Ball S, Peachey NS, Copenhagen D, Chapman B, Nakamoto M, Barres BA, Perin MS (2006) Neuronal pentraxins mediate synaptic refinement in the developing visual system. J Neurosci 26:6269–6281PubMedCrossRef
2.
Blouin AM, Thannickal TC, Worley PF, Baraban JM, Reti IM, Siegel JM (2005) Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy. Neurology 65:1189–1192PubMedCrossRef
3.
Crocker A, Espana RA, Papadopoulou M, Saper CB, Faraco J, Sakurai T, Honda M, Mignot E, Scammell TE (2005) Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 65:1184–1188PubMedCrossRef
4.
Decraene C, Brugg B, Ruberg M, Eveno E, Matingou C, Tahi F, Mariani J, Auffray C, Pietu G (2002) Identification of genes involved in ceramide-dependent neuronal apoptosis using cDNA arrays. Genome Biol 3:RESEARCH0042
5.
Dorsey DA, Masco DH, Dikranian K, Hyrc K, Masciotra L, Faddis B, Soriano M, Gru AA, Goldberg MP, de Erausquin GA (2006) Ultrastructural characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-induced cell death in embryonic dopaminergic neurons. Apoptosis 11:535–544PubMedCrossRef
6.
Duke DC, Moran LB, Kalaitzakis ME, Deprez M, Dexter DT, Pearce RK, Graeber MB (2006) Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson’s disease. Neurogenetics 7:139–148PubMedCrossRef
7.
8.
Fox MA, Umemori H (2006) Seeking long-term relationship: axon and target communicate to organize synaptic differentiation. J Neurochem 97:1215–1231PubMedCrossRef
9.
Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG, Lammers GJ, Swaab DF (2007) Hypocretin (orexin) loss in Parkinson’s disease. Brain 130:1577–1585PubMedCrossRef
10.
Fukumoto M, Iwata M, Shinbori C, Hazama GI, Shirayama Y, Kawahara R (2005) Effects of acute administration of methamphetamine on Narp mRNA in rat brain. Addict Biol 10:257–259PubMedCrossRef
11.
Goodman AR, Cardozo T, Abagyan R, Altmeyer A, Wisniewski HG, Vilcek J (1996) Long pentraxins: an emerging group of proteins with diverse functions. Cytokine Growth Factor Rev 7:191–202PubMedCrossRef
12.
Graeber MB, Grasbon-Frodl E, Abell-Aleff P, Kosel S (1999) Nigral neurons are likely to die of a mechanism other than classical apoptosis in Parkinson’s disease. Parkinsonism Relat Disord 5:187–192CrossRefPubMed
13.
Graeber MB, Moran LB (2002) Mechanisms of cell death in neurodegenerative diseases: fashion, fiction, and facts. Brain Pathol 12:385–390PubMedCrossRef
14.
Hsu YC, Perin MS (1995) Human neuronal pentraxin II (NPTX2): conservation, genomic structure, and chromosomal localization. Genomics 28:220–227PubMedCrossRef
15.
Kirkpatrick LL, Matzuk MM, Dodds DC, Perin MS (2000) Biochemical interactions of the neuronal pentraxins. Neuronal pentraxin (NP) receptor binds to taipoxin and taipoxin-associated calcium-binding protein 49 via NP1 and NP2. J Biol Chem 275:17786–17792PubMedCrossRef
16.
17.
McAllister AK (2000) Cellular and molecular mechanisms of dendrite growth. Cereb Cortex 10:963–973PubMedCrossRef
18.
Michael GJ, Averill S, Nitkunan A, Rattray M, Bennett DL, Yan Q, Priestley JV (1997) Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord. J Neurosci 17:8476–8490PubMed
19.
Moran LB, Duke DC, Deprez M, Dexter DT, Pearce RK, Graeber MB (2006) Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson’s disease. Neurogenetics 7:1–11PubMedCrossRef
20.
Moran LB, Croisier E, Duke DC, Kalaitzakis ME, Roncaroli F, Deprez M, Dexter DT, Pearce RK, Graeber MB (2007) Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra. Acta Neuropathol (Berlin) 113:253–263CrossRef
21.
Mueller HT, Haroutunian V, Davis KL, Meador-Woodruff JH (2004) Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Brain Res Mol Brain Res 121:60–69PubMedCrossRef
22.
O’Brien RJ, Xu D, Petralia RS, Steward O, Huganir RL, Worley P (1999) Synaptic clustering of AMPA receptors by the extracellular immediate-early gene product Narp. Neuron 23:309–323PubMedCrossRef
23.
O’Brien R, Xu D, Mi R, Tang X, Hopf C, Worley P (2002) Synaptically targeted narp plays an essential role in the aggregation of AMPA receptors at excitatory synapses in cultured spinal neurons. J Neurosci 22:4487–4498PubMed
24.
Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I (2005) Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57:82–91PubMedCrossRef
25.
Peirson SN, Butler JN, Foster RG (2003) Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Res 31:e73PubMedCrossRef
26.
Reti IM, Baraban JM (2003) Opiate withdrawal induces Narp in the extended amygdale. Neuropsyopharmacol 28:1606–1613CrossRef
27.
Reti IM, R Reddy R, Worley PF, Baraban JM (2002) Selective expression of Narp, a secreted neuronal pentraxin, in orexin neurons. J Neurochem 82:1561–1565PubMedCrossRef
28.
Steinberg JP, Huganir RL, Linden DJ (2004) N-ethylmaleimide-sensitive factor is required for the synaptic incorporation and removal of AMPA receptors during cerebellar long-term depression. Proc Natl Acad Sci 101:18212–18216PubMedCrossRef
29.
Storr HL, Clark AJ, Priestley JV, Michael GJ (2005) Identification of the sites of expression of triple A syndrome mRNA in the rat using in situ hybridisation. Neuroscience 131:113–123PubMedCrossRef
30.
Thannickal TC, Lai YY, Siegel JM (2007) Hypocretin (orexin) cell loss in Parkinson’s disease. Brain 130:1586–1595PubMedCrossRef
31.
Tsui CC, Copeland NG, Gilbert DJ, Jenkins NA, Barnes C, Worley PF (1996) Narp, a novel member of the pentraxin family, promotes neurite outgrowth and is dynamically regulated by neuronal activity. J Neurosci 16:2463–2478PubMed
32.
Xu D, Hopf C, Reddy R, Cho RW, Guo L, Lanahan A, Petralia RS, Wenthold RJ, O’Brien RJ, Worley P (2003) Narp and NP1 form heterocomplexes that function in developmental and activity-dependent synaptic plasticity. Neuron 39:513–528PubMedCrossRef
Metadata
Title
Neuronal pentraxin II is highly upregulated in Parkinson’s disease and a novel component of Lewy bodies
Authors
Linda B. Moran
Lorraine Hickey
Gregory J. Michael
Maria Derkacs
Lynne M. Christian
Michail E. Kalaitzakis
Ronald K. B. Pearce
Manuel B. Graeber
Publication date
01-04-2008
Publisher
Springer-Verlag
Published in
Acta Neuropathologica / Issue 4/2008
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-007-0309-3

Other articles of this Issue 4/2008

Acta Neuropathologica 4/2008 Go to the issue

Original Paper

Cortical α-synuclein load is associated with amyloid-β plaque burden in a subset of Parkinson’s disease patients

Editorial

Clarifying the pathological progression of Parkinson’s disease

Original Paper

Morphometry of the human substantia nigra in ageing and Parkinson’s disease

Original Paper

Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease

Editorial

A not entirely benign procedure: progression of Parkinson’s disease

Original Paper

α-Synuclein pathology in the neostriatum in Parkinson’s disease